Bifido

At a glance

Bifido filed 14 disclosures in the last 12 months, including 1 m&a. The most recent key filing was on Apr 9.

Revenue for 2025 was ₩19.7B, up 59.3% on 2024. Operating margin was 7.1% against -36.4% a year earlier. Debt was 33% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩6.1B and operating loss of ₩1B.

The 2025 annual report lists 102 employees with an average tenure of 5.2 years and average pay of ₩42.5M, #1706 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩83.8M each on average. It paid no cash dividend for 2025. 환인제약(주) and related parties held 31.10% at year end.

From the 2025 annual report

Staff: 102 (67 men, 35 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩4.3B. Directors and auditors: 5, paid ₩419.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

환인제약(주) holds 30.00%; with 1 related party the group holds 31.10% of common shares at year end.

Auditor: 우리회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary